mCRPC Treatment: From the Editor
1-20 of 30 Next
Minding the Gaps in Prostate Cancer Treatment
Communication with patients is always a challenge, as is gathering all the information you need to make an informed decision. Then there’s the energy and time that are required to keep up with the clinical literature in your space, and the scientific/basic literature of it if you are so inclined.
Preserve! Prevent! Prolong! (Embrace these as the goals of care)
1. Dear Surgeons - stop telling patients “We got it all” signed, Medical Oncologists.
2. Dear Medical Oncologists – please inform your patients that your treatments for metastatic disease are palliative, not curative. Signed, Surgeons and Radiation Oncologists.
What Should We Do with the Exceptional Responders?
Small Cells, Big Worries
The Year in mCRPC – an Unobjective Look at Some of 2018’s Best Papers
RB, or Not RB: That is the Question!
Apollo 14 and the Lessons from Fractures
In Search of the Ultimate Cause of Cancer Death and Survival
My institution, the University of Minnesota, recently launched a “Medical Discovery Team on the Biology of Aging” a program that brings together clinicians,
The Positive in the Negative
Or, I might be working on the design of the phase III study of BEZ235 in mCRPC, or the use of AMG-102 plus mitoxantrone in patients following docetaxel for mCRPC.
New Metastatic Prostate Cancer? First, Take a Deep BREATH
Abiraterone + Enzalutamide: Is it Love or just a PLATOnic Relationship? - Charles Ryan
How Do We Know When What We are Doing isn't Working? - Charles Ryan
Landmarks, Surrogates and Strategies for Accelerating Clinical Trial Results - Charles Ryan
Good Abi, Bad Abi - Charles Ryan
Genomically Guided Therapy for Prostate Cancer. Promise Unfulfilled, Misguided or too Early to Call? - Charles Ryan
Wherefore Art Thou, Provenge? - Charles Ryan
A meditation on the need and utility for Sip T in 2018. On a nearly weekly basis I am confronted by the question of whether I should be giving a patient Sipuleucel T. I still use it, but not in all my CRPC patients, and I like to think of this therapy as having a reasonable benefit for patients - who are at an early point in the CRPC spectrum. I will explain but first let’s review the data and its limitations.
Five Ways that Writing a Book Improved my Care of CRPC Patients - Charles Ryan
Non metastatic CRPC: The Five Essentials - Charles Ryan
Riding High on MSI - Charles Ryan
Ok, now that I have your attention, let’s talk about the science, the clinical care and the implications for the field.
But first, a brief case. Consider my patient Arnold (not his real name). He is a 68-year old man who underwent radical prostatectomy in 2011.
“Apollothirteenize” the Trial that Fractures Broke - Charles Ryan
1-20 of 30 Next